Success of Adjuvant Chemotherapy Trials for Gastric Cancer
Though surgery is the treatment modality of choice for many solid cancers, a rational approach seems to incorporate multimodal therapy into the treatment strategy for moderately locally advanced gastric cancer, as surgery cannot completely control micrometastasis. The rationale for adjuvant chemotherapy has been established by animal experiments [1, 2, 3], but the survival benefit of adjuvant chemotherapy is not always observed clinically for many solid cancers. The discrepancy between animal and clinical treatments should be thoroughly studied to improve the current treatment results. This paper reports the rationale for adjuvant chemotherapy derived from animal experiments, an analysis of the discrepancies between animal and clinical treatment results, and some discussion of possible pathways to future trials [4, 5, 6].
KeywordsGastric Cancer Adjuvant Chemotherapy Clin Oncol Tumor Burden Advanced Gastric Cancer
Unable to display preview. Download preview PDF.
- 8.Nakajima T, Nishi M (1988) Adjuvant chemotherapy, immunochemotherapy, and neoadjuvant therapy for gastric cancer in Japan. In: Douglass HO Jr (ed) Gastric cancer. Churchill Livingstone, New York, pp 125–143Google Scholar
- 9.Douglass H Jr (1988) Western surgical adjuvant trials in gastric cancers: lessons from current trials to be applied to the future. In: Douglass HO, Jr (ed) Gastric cancer. Churchill Livingstone, New York, pp 145–172Google Scholar
- 15.Koizumi W, Kurihara M, Sasai T, Yoshida S, Morise K, Imamura A, Akazawa S, Betsuyaku T, Ohkubo S, Takahashi H, Akiya T, Hamada T, Kiyohashi A (1993) A phase II study of combination therapy with 5′-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci. Cancer 72:658–662PubMedCrossRefGoogle Scholar
- 17.Preusser P, Wilke H, Achterrath W, Fink U, Meyer J, Meyer HJ, Van de Loo J (1987) Phase-II-Studie mit Etoposid, Adriamycin, Cisplatin (EAP) beim primaer inoperablen, metastasierten Magenkarzinom. Tumor Diagn Ther 8:43–48Google Scholar
- 20.Shirao K, Shimada Y, Kondo H, Saito D, Yamao T, Ono H, Yokoyama T, Fukuda H, Oka M, Watanabe Y, Ohtsu A, Boku N, Fujii T, Oda Y, Muro K, Yoshida S (1997) Phase I–II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 15:921–927PubMedGoogle Scholar
- 21.Horikoshi N, Mitachi Y, Sugimachi K, Taguchi T, Group S1CS (1996) New oral fluoropyrimidine is very active in patients with advanced gastric cancer (early phases II study). Proc ASCO 15:206Google Scholar